Heather Day
Acute Care · Greenville, NCNPI 1952601338
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,082 of the $4,600 with a category attached, or 67.0%. 18 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 38.8% of the total. Reporting peaked in 2021 at $2,084 and has fallen 88.7% since, to $237 in 2025. Among acute care clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- E.r. Squibb & Sons, L.L.C.$475
- AstraZeneca$399
- Novartis$297
- Johnson & Johnson$296
- Pfizer$249
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$1,50033%
- Food & beverage$3,08267%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $1,785 |
| E.r. Squibb & Sons, L.L.C. | 26 | $475 |
| AstraZeneca | 13 | $399 |
| Novartis | 19 | $297 |
| Johnson & Johnson | 16 | $296 |
| Pfizer | 15 | $249 |
| Boehringer Ingelheim | 11 | $196 |
| Abiomed | 3 | $189 |
| Merck | 9 | $133 |
| Cvrx, Inc. | 9 | $118 |
| Scpharmaceuticals Inc. | 4 | $103 |
| Abbott | 5 | $94 |
| United Therapeutics Corporation | 3 | $70 |
| Bayer | 4 | $55 |
| Actelion Pharmaceuticals US, Inc. | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Pharmacosmos Therapeutics Inc. | 1 | $32 |
| Amgen | 2 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,600 in reported general payments places this provider in the 90th percentile of 312 acute care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 44 | $1,015,740 |
| OpsumitMacitentan | 66 | $838,344 |
| UptraviSelexipag | 23 | $659,815 |
| EntrestoSacubitril/Valsartan | 561 | $536,595 |
| JardianceEmpagliflozin | 437 | $369,417 |
| FarxigaDapagliflozin Propanediol | 231 | $185,596 |
| EliquisApixaban | 134 | $100,531 |
| XareltoRivaroxaban | 76 | $49,747 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 68 | $14,637 |
| Bumetanide | 293 | $10,634 |
| Sildenafil Citrate | 29 | $9,950 |
| Torsemide | 334 | $6,805 |
| Repatha SureclickEvolocumab | 11 | $5,610 |
| Metoprolol Succinate | 459 | $5,295 |
| Spironolactone | 783 | $4,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $48 | $1,498,15989 claims |
| PfizerVyndamax, Eliquis | $249 | $1,116,271178 claims |
| NovartisEntresto | $297 | $536,595561 claims |
| Boehringer IngelheimJardiance | $196 | $369,417437 claims |
| AstraZenecaFarxiga | $399 | $185,596231 claims |
| Johnson & JohnsonXarelto | $296 | $49,74776 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 acute care providers in North Carolina.
Other acute care in Greenville
- Benjamin HocuttGreenville$25K
- Shalaila SalazarGreenville$6K
- Ashley SchneiderGreenville$6K
- Cora KearleyGreenville$3K
- Jennifer MurphyGreenville$3K
- Chloe LintonGreenville$2K
- Kelly KittleGreenville$2K
- Melissa FulmerGreenville$2K
- Matthew KuhnPinehurst$16K
- Robin TruppApex$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.